Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Third Rock launches Sage with $35M Series A to address CNS pathways

This article was originally published in Scrip

Executive Summary

The latest start-up from the Third Rock Ventures stable, Sage Therapeutics, has been formally launched, to develop treatments for central nervous system disorders. With a Series A funding of $35 million, Sage will be basing its R&D on allosteric receptor modulation, where the goal is not to simply turn a receptor on or off, the way most drugs act, but to develop allosteric modulators that offer control over the intensity of receptor activation and thus restoring the balance to the activity of the primary excitatory and inhibitory neurotransmitter systems of the brain.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts